| ID | 1174 |
| Name of the vaccine | mv rOspA LB |
| Microbe | Bacteria |
| Disease name | Lyme disease (Lyme borreliosis) |
| Name of bacteria | Borrelia burgdorferi |
| Type of vaccine | Recombinant |
| Nucleic acid content | DNA |
| Age | 18 to 70 years |
| Description of the vaccine | Multivalent recombinant OspA Lyme Borreliosis vaccine. |
| Name of the manufacturer | Baxalta now part of Shire |
| Name of the manufacturing country | Austria, Germany |
| Year of manufacture | 2014 |
| Clinical Phase status | Clinical - Phase 1, Phase 2 |
| Bacterial strain | Gram-negative spirochete bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three primary doses and one booster dose. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | With or without adjuvant |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | Yes (from the bite of infected blacklegged ticks) |
| PubMed identifier | NA |
| Clinical trial number | NCT01504347 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|